A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule.
Fyfe D, Price C, Langley RE, Pagonis C, Houghton J, Osborne L, Woll PJ, Gardner C, Baguley BC, Carmichael J; Cancer Research Campaing Phase I/II Trials Committee.
Fyfe D, et al. Among authors: gardner c.
Cancer Chemother Pharmacol. 2001 Apr;47(4):333-7. doi: 10.1007/s002800000216.
Cancer Chemother Pharmacol. 2001.
PMID: 11345650
Clinical Trial.